Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update

Citius Oncology, Inc. (NASDAQ:CTOR) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 650,544 shares, an increase of 193.4% from the November 30th total of 221,699 shares. Based on an average trading volume of 933,057 shares, the short-interest ratio is currently 0.7 days. Currently, 0.8% of the shares of the company are short sold. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 933,057 shares, the short-interest ratio is currently 0.7 days.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on CTOR shares. Maxim Group raised shares of Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, September 23rd. Citigroup upgraded Citius Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, September 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Investors Weigh In On Citius Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in shares of Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after acquiring an additional 8,411 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in Citius Oncology in the second quarter valued at approximately $51,000. Citadel Advisors LLC purchased a new stake in Citius Oncology during the 3rd quarter valued at $36,000. IFP Advisors Inc grew its stake in shares of Citius Oncology by 49.5% in the third quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock worth $67,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Citius Oncology by 179.0% during the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after acquiring an additional 36,758 shares in the last quarter. Institutional investors own 70.52% of the company’s stock.

Citius Oncology Stock Down 1.3%

CTOR stock traded down $0.02 during trading on Friday, reaching $1.13. 307,556 shares of the stock were exchanged, compared to its average volume of 968,080. Citius Oncology has a twelve month low of $0.55 and a twelve month high of $6.19. The firm has a market cap of $95.82 million, a P/E ratio of -3.32 and a beta of 2.98. The firm’s 50 day moving average is $1.36 and its 200 day moving average is $1.89. The company has a current ratio of 0.56, a quick ratio of 0.02 and a debt-to-equity ratio of 0.08.

Citius Oncology (NASDAQ:CTOR) last announced its earnings results on Tuesday, December 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06).

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.